“…1998;55:918-924 A LTHOUGH controlled studies have demonstrated the superiority of serotonin reuptake inhibitors (SRIs) over placebo in reducing symptoms of obsessive-compulsive disorder (OCD), the response is often limited. [1][2][3] Uncontrolled clinical reports have suggested that clomipramine administered intravenously (IV) is effective for OCD [4][5][6] and that it may act more rapidly and be more effective, 7 even among patients who have not responded to oral clomipramine. [8][9][10] Summarizing his experience with 30 patients with OCD treated with IV clomipramine in an open setting, Warneke 10 noted that 14 consecutive weekday IV clomipramine infusions starting at 25 mg and building to 350 mg appeared to be safe, well tolerated, and effective for some oral clomipraminerefractory or oral clomipramine-intolerant patients.…”
Intravenous clomipramine is more effective than i.v. placebo for patients with OCD with a history of inadequate response or intolerance to oral clomipramine. Further study of this promising treatment for refractory OCD is needed.
“…1998;55:918-924 A LTHOUGH controlled studies have demonstrated the superiority of serotonin reuptake inhibitors (SRIs) over placebo in reducing symptoms of obsessive-compulsive disorder (OCD), the response is often limited. [1][2][3] Uncontrolled clinical reports have suggested that clomipramine administered intravenously (IV) is effective for OCD [4][5][6] and that it may act more rapidly and be more effective, 7 even among patients who have not responded to oral clomipramine. [8][9][10] Summarizing his experience with 30 patients with OCD treated with IV clomipramine in an open setting, Warneke 10 noted that 14 consecutive weekday IV clomipramine infusions starting at 25 mg and building to 350 mg appeared to be safe, well tolerated, and effective for some oral clomipraminerefractory or oral clomipramine-intolerant patients.…”
Intravenous clomipramine is more effective than i.v. placebo for patients with OCD with a history of inadequate response or intolerance to oral clomipramine. Further study of this promising treatment for refractory OCD is needed.
“…amitriptyline and most importantly chlorimipramine [Angst and Theo bald, 1970;Beaumont. 1973;Marshall, 1971;Capstick, 1975;Rach. 1973;Walters, 1973;Snyder, 1980b;Hus sain and Ahad, 1970;Bauer and Nowak, 1969;Ananth et al, 1975;Lopez-lbor, 1969].…”
Section: Pharmacologic Evidencementioning
confidence: 99%
“…Anecdotal reports of improvement in 36 of 51 obsessional patients with CMI prompted more extensive clinical trials [Beaumont, 1973;Marshall, 1971;Capstick. 1975;Rach, 1973: Wal ters, 1973. Investigators using high-dose CMI adminis tered intravenously [Walters, 1973;Lopez-lbor, 1969] and orally [Ananth et al, 1979] demonstrated treatment efficacy in open studies.…”
There is scant but provocative evidence to support the concept of a biological etiology in obsessive-compulsive disorder (OCD). This evidence includes the phenomenologic similarities and associations with other major psychiatric disorders for which there is evidence of biologic etiologies; the genetic studies that show an increased familial occurrence of psychiatric illness including OCD and concordance for this disorder in monozygotic twins; biologic evidence and the historical association of OCD and CNS damage; the treatment response of OCD to antidepressant medication and possibly those medications that selectively modify serotonin neuronal activity and to selective anterior limbic leukotomy. This evidence and the evidence linking OCD to depressive illness are specifically reviewed and discussed.
“…Further studies of the inventory by Cooper & Kelleher (1973) (Capstick, 1973;Rack, 1973;Marshall & Micev, 1973;Walter, 1973). Other drugs merit inclusion in future trials.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.